Sands Capital Management LLC Lowers Stock Holdings in DexCom, Inc. $DXCM

Sands Capital Management LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 50.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,934,189 shares of the medical device company’s stock after selling 5,013,755 shares during the period. Sands Capital Management LLC owned approximately 1.27% of DexCom worth $332,022,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom during the second quarter worth approximately $26,000. SJS Investment Consulting Inc. increased its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the period. Financial Consulate Inc. acquired a new position in DexCom in the 3rd quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom during the 2nd quarter worth $45,000. Finally, Sound Income Strategies LLC raised its position in DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after buying an additional 285 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ DXCM opened at $67.79 on Wednesday. The business has a 50 day moving average price of $70.73 and a 200 day moving average price of $68.57. The company has a market capitalization of $26.09 billion, a P/E ratio of 32.28, a PEG ratio of 1.34 and a beta of 1.48. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.45 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. Mizuho lifted their target price on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Robert W. Baird set a $87.00 price objective on shares of DexCom in a research report on Friday, February 13th. Barclays reiterated an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 price target (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Finally, Citigroup restated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.